Written by students who passed Immediately available after payment Read online or as PDF Wrong document? Swap it for free 4.6 TrustPilot
logo-home
Document preview thumbnail
Preview 4 out of 36 pages
Exam (elaborations)

NR 668 CEA Final 2026/2027 – Chamberlain University PMHNP Psychopharmacology & Neuroscience Practice Questions with Verified Answers

Document preview thumbnail
Preview 4 out of 36 pages

This focused practice question bank is specifically designed for the NR 668 Clinical Evaluation and Assessment (CEA) Final at Chamberlain University, offering advanced coverage of Psychopharmacology and Neuroscience content for the 2026/2027 academic year. This high-yield resource addresses all essential topics related to psychiatric pharmacotherapy and neurobiology, including mechanisms of action of antidepressants (SSRIs, SNRIs, MAOIs, TCAs), antipsychotics (typical and atypical), mood stabilizers (lithium, anticonvulsants), anxiolytics and sedative-hypnotics, stimulants and non-stimulants for ADHD, neurobiological underpinnings of psychiatric disorders (depression, schizophrenia, bipolar disorder, anxiety disorders, PTSD, substance use disorders), neurotransmitter systems (dopamine, serotonin, norepinephrine, GABA, glutamate), pharmacodynamics and pharmacokinetics, drug-drug interactions and adverse effects, prescribing considerations across the lifespan, monitoring parameters and laboratory testing, and integration of psychopharmacology with psychotherapy and psychosocial interventions. Each question is paired with verified answers and detailed rationales to strengthen clinical reasoning, reinforce advanced practice knowledge, and ensure thorough preparation for this capstone examination. Developed exclusively for Chamberlain PMHNP students preparing for the NR 668 CEA Final, this psychopharmacology and neuroscience question bank serves as an essential tool for targeted exam readiness. By engaging with these exam-aligned questions and studying the accompanying rationales, candidates can systematically evaluate their knowledge, identify areas requiring additional review, and build the confidence necessary to succeed on the CEA Final. This resource is vital for demonstrating competency in psychopharmacology, neurobiology, and psychiatric medication management in advanced practice psychiatric nursing. Vertical Keywords NR 668 CEA Final Chamberlain University PMHNP Psychopharmacology Practice Questions Neuroscience PMHNP Psychiatric Medication Management Antidepressant Mechanisms Antipsychotic Pharmacology Neurotransmitter Systems PMHNP Capstone Exam Psychotropic Drug Interactions Verified NR 668 Answers CEA Final Exam Prep

Content preview

PMHNP BOARD

PASS.
CHAMBERLAIN UNIVERSITY · COLLEGE OF NURSING


NR 668 CEA Final — Part 2
Practice Question Bank

Psychopharmacology, Neuroscience & Psychiatric Disorders



COMPREHENSIVE REVIEW:
Medication Management, Neuroanatomy & Psychotherapy
— DSM-5 Diagnoses & Clinical Decision-Making



CEA Final Part 2 — Edition 1 · July 2026




EXAM FOCUSED DETAILED 90+ QUESTIONS BUILD CONFIDENCE
RATIONALES
Aligned with NR 668 CEA Complete psychopharm & Pass your NR 668 CEA Final
objectives Clear explanations for mastery neuro coverage




P r e pa r e · P r a c t i c e · Pa s s

Excellence in PMHNP Certification

,NR 668 CEA FINAL — PART 2 QUESTIONS 1–30



Section 1: Substance Use, Psychotherapy & Mental Status Exam


1 A 26-year-old female with 6-year opioid use disorder on buprenorphine
for 4 months is in early remission. She questions continuing
buprenorphine. What is the best course of action?

A Educate the patient on the benefit of continuing buprenorphine for 1-2
more years
B Discontinue buprenorphine and follow serial urine drug screens
C Explore changing from buprenorphine to methadone
D Taper buprenorphine over 2 months as the patient requests


CORRECT ANSWER: A

RATIONALE: Early remission does not mean cure — buprenorphine
maintenance for 1-2 more years reduces relapse risk and supports sustained
recovery. Premature discontinuation significantly increases relapse
potential. The patient's functional improvement is evidence the medication
is working, not that it is no longer needed.

,2 A 30-year-old man with schizoaffective disorder received court-ordered
Zyprexa Relprevv. He states he knows smoking can "make him need more
medication." Which stage of change is he in?

A Contemplation — aware of the problem and considering change
B Action — actively making changes
C Preparation — planning to take action soon
D Maintenance — sustaining changes over time


CORRECT ANSWER: A

RATIONALE: Contemplation involves recognizing a problem and
considering the possibility of change without yet committing to action. The
patient acknowledges smoking affects his medication needs but has not yet
taken steps to quit — this is classic contemplation.




3 A 16-year-old client Jamie states "I might be transgender" and prefers
pronouns "They." The PMHNP recognizes Jamie:

A Identifies as non-binary — not identifying exclusively with male or female
gender
B Identifies as cisgender
C Identifies as gender binary
D Identifies as none of these


CORRECT ANSWER: A

RATIONALE: Non-binary individuals do not identify exclusively as male or
female. They/them pronouns are commonly used by non-binary persons.
Cisgender means identifying with the sex assigned at birth. Gender binary
refers to the traditional male/female dichotomy.

, 4 Which immediate determinant related to relapse prevention is the
biggest predictor of relapse?

A Negative emotional state
B Ineffective coping skills
C Previous history of lapse
D Outcome expectancy


CORRECT ANSWER: A

RATIONALE: Negative emotional states (stress, anger, depression, anxiety)
are the strongest immediate predictors of relapse across substance use
disorders. While ineffective coping and previous lapses contribute, the
acute experience of negative affect most directly triggers return to use.




5 The mental status exam includes all of the following EXCEPT:

A Cranial nerves and reflexes — these are part of the neurological exam, not
the MSE
B Mood and affect
C Appearance and behavior
D Insight and judgment


CORRECT ANSWER: A

RATIONALE: The MSE assesses current mental functioning: appearance,
behavior, mood, affect, speech, thought process, thought content,
perception, cognition, insight, and judgment. Cranial nerves and reflexes
belong to the neurological examination, which is a separate assessment.

Document information

Uploaded on
July 24, 2026
Number of pages
36
Written in
2025/2026
Type
Exam (elaborations)
Contains
Questions & answers
$13.49

Wrong document? Swap it for free Within 14 days of purchase and before downloading, you can choose a different document. You can simply spend the amount again.
Written by students who passed
Immediately available after payment
Read online or as PDF

Seller avatar
Reputation scores are based on the amount of documents a seller has sold for a fee and the reviews they have received for those documents. There are three levels: Bronze, Silver and Gold. The better the reputation, the more your can rely on the quality of the sellers work.
DrEmma
4.1
(8)
Sold
59
Followers
2
Items
1540
Last sold
3 hours ago


Why students choose Stuvia

Created by fellow students, verified by reviews

Quality you can trust: written by students who passed their tests and reviewed by others who've used these notes.

Didn't get what you expected? Choose another document

No worries! You can instantly pick a different document that better fits what you're looking for.

Pay as you like, start learning right away

No subscription, no commitments. Pay the way you're used to via credit card and download your PDF document instantly.

Student with book image

“Bought, downloaded, and aced it. It really can be that simple.”

Alisha Student

Working on your references?

Create accurate citations in APA, MLA and Harvard with our free citation generator.

Working on your references?

Frequently asked questions